FAQ
Frequently asked questions
These are the practical questions overseas sponsors ask when they are weighing Australia as a trial location and deciding whether to appoint a local sponsor instead of forming an Australian entity.
Why does an overseas company need an Australian local sponsor?
Clinical trials conducted in Australia need an Australian entity to hold the sponsor role. If the overseas company does not have an Australian entity, it needs an Australian local sponsor for the study.
Can we run an Australian study without setting up our own subsidiary?
Yes, if local sponsorship is suitable for the study. Clintrail can hold the Australian sponsor role, which avoids setting up and maintaining a local company solely to sponsor the Australian trial.
How does using Clintrail save time?
It removes the need to incorporate an Australian entity before startup. That can shorten the path to an Australian sponsor structure and lets the overseas team focus on protocol, sites, approvals, budget, and study delivery.
How does using Clintrail reduce cost and administrative burden?
Forming a local entity brings establishment, governance, accounting, tax, and ongoing administration. For sponsors testing Australia for one study or an early program, appointing Clintrail can be a cleaner alternative to building local corporate infrastructure too early.
Why do overseas sponsors choose Australia for clinical trials?
Australia is attractive because it has experienced clinical trial sites, established ethics and governance processes, recognised GCP expectations, and a CTN pathway commonly used for studies involving unapproved therapeutic goods. Eligible R&D activity may also access Australian tax incentives, subject to separate advice and eligibility.
Does Clintrail help overseas sponsors benefit from Australia faster?
Clintrail helps with one important blocker: the need for an Australian sponsor entity. That does not replace ethics approval, site activation, contracts, insurance, tax advice, or study operations, but it can remove the need to create a company before those workstreams progress.
Is this relevant for medical device and diagnostics companies?
Yes. Medical device, diagnostics, biotech, and pharma companies may all face the same practical issue: the Australian sponsor role must be held locally. Suitability depends on the product, study design, regulatory pathway, and proposed Australian footprint.
Can Clintrail act as sponsor for medical device trials?
Yes. Clintrail can act as the Australian sponsor for eligible medical device clinical trials where the Australian sponsor role, device responsibilities, site model, safety reporting, insurance, and governance arrangements are clearly defined.
Can Clintrail act as sponsor for diagnostics or IVD studies?
Yes. Diagnostics and IVD studies can also require an Australian sponsor. The responsibility split should address the assay or device, specimen handling, laboratory arrangements, data strategy, safety reporting, and the intended Australian clinical trial pathway.
Does Clintrail support CTN and CTA studies?
Clintrail can support Australian sponsorship for studies where the CTN or CTA pathway is relevant. The appropriate pathway depends on the product, risk profile, clinical trial design, and Australian regulatory strategy.
What documents should we have ready before speaking with Clintrail?
Useful documents include a protocol or synopsis, product summary, proposed Australian site list, development stage, intended CTN or CTA pathway if known, insurance or indemnity assumptions, safety reporting plan, and any draft responsibility matrix.
Can we keep our global operating model while appointing Clintrail in Australia?
Yes. Overseas companies often keep global product ownership, clinical strategy, funding control, vendor oversight, and broader program leadership while appointing Clintrail to hold the Australian sponsor role for the Australian clinical trial.
Does Clintrail replace our clinical operations, regulatory, or legal teams?
No. Clintrail acts as the Australian local sponsor. The overseas sponsor still retains product ownership, protocol strategy, global development decisions, budget control, and the broader development program.
Does Clintrail replace HREC approval, site governance, or CTN preparation?
No. Those workstreams still need to be handled by the appropriate parties. Clintrail's role is the Australian sponsor role; the study still needs the relevant ethics, governance, regulatory, insurance, contractual, and operational arrangements.
What stays with the overseas sponsor?
The overseas sponsor retains product ownership, IP, global program leadership, protocol strategy, funding responsibility, and decisions about the wider development plan. The local sponsor role should be clearly defined so both sides know where responsibility sits.
Is Australia suitable for first-in-human or early feasibility studies?
Australia is often considered for early-stage studies because of its clinical research capability and established CTN pathway. Whether it is right for a specific first-in-human, feasibility, device, diagnostics, or drug study depends on product risk, protocol design, site capability, and regulatory strategy.
Can Australian clinical trial data support overseas development plans?
Australian studies are commonly designed as part of broader global development programs. The value of the data for overseas regulatory or commercial purposes depends on the study design, endpoints, conduct, population, and the expectations of the relevant overseas regulators.
What information should we include in an initial enquiry?
Useful starting information includes the sponsor company, product type, trial phase or development stage, whether it is drug, device, diagnostics, or other therapeutic goods, expected Australian sites, target startup timing, and why a local sponsor is needed.
What happens after we submit an enquiry?
Clintrail reviews the enquiry and gets back to you soon. The next discussion can cover the study, proposed Australian structure, responsibilities, and timing.
The key point
The core question is simple.
Is Australia the right jurisdiction for the study, and is it more efficient to appoint an Australian local sponsor than to establish a local company before the trial begins?
Clintrail's answer
Clintrail is built for exactly that situation.
Clintrail can hold the Australian sponsor role while the overseas sponsor keeps product ownership, global strategy, funding control, and the broader development program.
Next step
Ask about your study directly
Submit an enquiry with the study outline, sponsor company, and intended Australian scope. Clintrail will review it and get back to you soon.